Literature DB >> 8494359

Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

W W Barrow1, E L Wright, K S Goh, N Rastogi.   

Abstract

Smooth- and rough-colony variants of Mycobacterium avium serovar 4 were treated with three classes of drugs. The drugs were chosen for their potential inhibitory effects on the biosynthesis of the cell envelope-associated serovar-specific glycopeptidolipid antigens. Growth was monitored radiometrically with a BACTEC 460-TB instrument, and MICs were determined for each drug. Both variants were then treated with inhibitory drugs in combination with antimicrobial agents that have demonstrated effectiveness against M. avium. No growth inhibition was observed with 6-fluoro-6-deoxy-D-glucose or avidin. Inhibitors of glycosylation, i.e., 2-deoxy-D-glucose, bacitracin, and ethambutol, were inhibitory to smooth- and rough-colony variants, whereas drugs that inhibit peptide synthesis, i.e., N-carbamyl-L-isoleucine and m-fluoro-phenylalanine, were more inhibitory for the rough-colony variant. Cerulenin, which affects fatty acid synthesis, was inhibitory for both variants, but it appeared to be more effective at inhibiting the growth of the smooth-colony variant at equivalent concentrations. Generally, when inhibitors of glycosylation were used with sparfloxacin and amikacin, a synergistic effect was observed for only the smooth variant. When drugs that affect peptide synthesis were used in combination with amikacin, a synergistic effect was observed for the rough variant, and when cerulenin was used in combination with sparfloxacin or amikacin, a synergistic effect was observed for both variants. Lipid analysis revealed that although the rough variant lacks the serovar-specific glycopeptidolipid antigens, it does possess a group of phenylalanine-isoleucine-containing lipopeptides that may explain its different susceptibility patterns to m-fluoro-phenylalanine and N-carbamyl-L-isoleucine. The significance of these results is discussed with reference to various components in the cell envelope and their importance in cell wall permeability.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494359      PMCID: PMC187730          DOI: 10.1128/AAC.37.4.652

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Ultrastructure of superficial mycosidic integuments of Mycobacterium sp.

Authors:  K S Kim; M R Salton; L Barksdale
Journal:  J Bacteriol       Date:  1976-02       Impact factor: 3.490

Review 2.  Nontuberculous mycobacteria and associated diseases.

Authors:  E Wolinsky
Journal:  Am Rev Respir Dis       Date:  1979-01

3.  The action mechanism of cerulenin. I. Effect of cerulenin on sterol and fatty acid biosynthesis in yeast.

Authors:  S Nomura; T Horiuchi; S Omura; T Hata
Journal:  J Biochem       Date:  1972-05       Impact factor: 3.387

4.  The nature of the electron-transparent zone that surrounds Mycobacterium lepraemurium inside host cells.

Authors:  P Draper; R J Rees
Journal:  J Gen Microbiol       Date:  1973-07

5.  Structural studies on the type-specific antigens and lipids of the mycobacterium avium. Mycobacterium intracellulare. Mycobacterium scrofulaceum serocomplex. Mycobacterium intracellulare serotype 9.

Authors:  P J Brennan; M B Goren
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

6.  The mycoside capsule of Mycobacterium Avium 357.

Authors:  P Draper
Journal:  J Gen Microbiol       Date:  1974-08

Review 7.  The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis.

Authors:  S Omura
Journal:  Bacteriol Rev       Date:  1976-09

Review 8.  Mycobacterium.

Authors:  L Barksdale; K S Kim
Journal:  Bacteriol Rev       Date:  1977-03

9.  Cerulenin.

Authors:  S Omura
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

10.  Peptidoglycolipid nature of the superficial cell wall sheath of smooth-colony-forming mycobacteria.

Authors:  W W Barrow; B P Ullom; P J Brennan
Journal:  J Bacteriol       Date:  1980-11       Impact factor: 3.490

View more
  10 in total

1.  Monoclonal infection involving Mycobacterium avium presenting with three distinct colony morphotypes.

Authors:  E L Wright; S Zywno-van Ginkel; N Rastogi; W W Barrow
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

2.  Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.

Authors:  N Rastogi; K S Goh; A Bryskier; A Devallois
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Immunomodulatory spectrum of lipids associated with Mycobacterium avium serovar 8.

Authors:  W W Barrow; T L Davis; E L Wright; V Labrousse; M Bachelet; N Rastogi
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

4.  Genes required for intrinsic multidrug resistance in Mycobacterium avium.

Authors:  Julie S Philalay; Christine O Palermo; Kirsten A Hauge; Tige R Rustad; Gerard A Cangelosi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium.

Authors:  W W Barrow; J P de Sousa; T L Davis; E L Wright; M Bachelet; N Rastogi
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.

Authors:  N Rastogi; K S Goh; E L Wright; W W Barrow
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

7.  Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.

Authors:  C B Inderlied; L Barbara-Burnham; M Wu; L S Young; L E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

8.  On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease.

Authors:  Ramon A Juste; Natalia Elguezabal; Joseba M Garrido; Andres Pavon; Maria V Geijo; Iker Sevilla; Jose-Luis Cabriada; Angel Tejada; Francisco García-Campos; Roberto Casado; Itziar Ochotorena; Ander Izeta; Robert J Greenstein
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

Review 9.  Warm, Sweetened Milk at the Twilight of Immunity - Alzheimer's Disease - Inflammaging, Insulin Resistance, M. paratuberculosis and Immunosenescence.

Authors:  Coad Thomas Dow
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

10.  On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis.

Authors:  Robert J Greenstein; Liya Su; Ramon A Juste; Sheldon T Brown
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.